单碳基黄素类似物 (MACs) 的生物活动的最新进展
Amol A Nagargoje1, Sharad P Panchgalle1, Madiha M Siddiqui2
1Department of Chemistry, Khopoli Municipal Council College, Khopoli, Maharashtra, India.
Archiv der Pharmazie
|December 3, 2025
概括
黄素的单碳基类似物 (MACs) 提高了黄素的生物可用性,提供了更好的治疗潜力. 这篇评论详细介绍了MACs.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 来自黄的黄素具有广泛的生物活性,但药理动力学不佳.
- 结构性修改导致了具有更好的生物可用性的黄素 (MACs) 的单碳烯类似物.
研究的目的:
- 审查MAC发展的最新进展.
- 专注于MAC的治疗特性和结构-活性关系 (SAR).
主要方法:
- 关于MACs最近研究的文献综述.
- 对各种MAC衍生品的SAR分析.
主要成果:
- MACs表现出显著的抗氧化,抗炎,抗结核,抗微生物,抗糖尿病,抗莱什曼和抗阿尔茨海默症活动.
- 特定的结构特征与增强的治疗疗效相关.
结论:
- MACs代表了一类有前途的化合物,具有改善的药理动力学特征.
- 对MAC的进一步研究可能会导致新的治疗药物.
关键词:
它具有抗糖尿病活性.它具有抗莱什曼的活性.抗微生物活性的抗微生物活性.抗氧化剂活性 抗氧化剂活性它具有抗结核活性.抗阿尔茨海默病的活性.它具有抗炎活性,具有抗炎活性.单碳尼尔库尔库明类似物 (MAC)更多相关视频
06:39Author Spotlight: Exploring Photodynamic Therapy with Curcumin in a Murine Model for Oral Candidiasis
Published on: October 27, 2023
1.4K
07:36Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea
Published on: December 23, 2022
1.9K
相关概念视频
01:24Cholinergic Antagonists: Pharmacokinetics
878
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
878
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
457
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
457